ABUS — Arbutus Biopharma Corp · P/E 5.4, rev $180.1M

Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.

Latest reported ABUS revenue for 2026-06-30 was $180.1M. Net income was $164.6M. Revenue was up 0.6% from 2026-03-31 to 2026-06-30. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.

Use this ABUS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ABUS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ABUS SEC filings page. Lician reads the product cache first so this HTML stays unique to Arbutus Biopharma Corp even when a live quote feed is slow.

Arbutus Biopharma Corp latest statements (FY2025)

Latest cached year on this hub. Full ABUS income, balance, and cash tables.

  • Revenue$14.1M
  • Net Income-$33.5M
  • Total Assets$94.6M
  • Total Debt$0
  • Free Cash Flow-$39.6M

ABUS recent filings